Besifovir dipivoxil (Besivo)
Small molecule
Evidence outlook
Approved: Chronic hepatitis B (KR)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Partial signal
Also approved (1)
- Chronic hepatitis B
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00895596 NCT00895596 · Chronic Hepatitis B Registry: NCT00895596 | 1/2 | Mean serum HBV DNA level (log10) reduction from the baseline at Week 12 2006-08 | Mean week-12 HBV DNA reduction was dose-dependent, from 2.81 to 4.16 log10 copies/mL across five ascending doses. | not yet graded | link ↗ |
View 2 more trials
NCT01026610 NCT01026610 · Chronic Hepatitis B Registry: NCT01026610 | 2 | Changes in HBV DNA level (log10) from baseline (At Week 24) 2010-11 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT01937806 NCT01937806 · Chronic Hepatitis B This was a randomized, double-blind Phase 3 trial in 197 patients with chronic hepatitis B comparing besifovir with tenofovir disoproxil fumarate. Its primary endpoint, virologic response at week 48, is the disease-defining measure and met the non-inferiority margin according to the published report. The sources read give no power calculation, so the grade is moderate. Registry: NCT01937806 | 3 | The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week 2016-02 | Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other HBV polymerase (reverse transcriptase) drugs
Entecavir (Baraclude), lamivudine (Epivir-HBV), tenofovir alafenamide (Vemlidy), Tenofovir amibufenamide (Hengmu), Entecavir (Cavir). Compare all 6 HBV polymerase (reverse transcriptase) drugs
7 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Chronic Hepatitis B: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Besifovir Dipivoxil (Besivo): this drug | Phase 3 | Small molecule | HBV polymerase (reverse transcriptase) | Partial signal | NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019). | |
| Entecavir (Baraclude) | Approved | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Hepatitis B Immune Globulin (HepaGam B) | Approved | Protein / enzyme therapeutic | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| Interferon Alfa-2b (Intron A) | Approved | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lamivudine (Epivir-HBV) | ApprovedUS marketing discontinued | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Peginterferon Alfa-2a (Pegasys) | Approved | — | Type I interferon receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Tenofovir Alafenamide (Vemlidy) | Approved | Small molecule | HBV polymerase (reverse transcriptase) | Reliable signal | Featured results are non-efficacy only in this race | |
| Tenofovir Disoproxil Fumarate (Viread) | Approved | Small molecule | HIV reverse transcriptase (RT) | Reliable signal | NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants | |
| Hepatitis B Immune Globulin (I.V.-Hepabig) | Phase 3 | Polyclonal Antibody (human Hepatitis B Immunoglobulin) | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| Tenofovir Amibufenamide (Hengmu) | Phase 3 | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3605 | Phase 3 | — | HBV core protein | not yet graded | No reviewed efficacy summary in this indication | |
| TVAX-008 | Phase 3 | Vaccine | Hepatitis B virus antigens (HBsAg + HBcAg) | not yet graded | No reviewed efficacy summary in this indication | |
| AHB-171 | Phase 2 | RNA / oligonucleotide | HBV RNA | not yet graded | No reviewed efficacy summary in this indication | |
| Daplusiran / Tomligisiran | Phase 2 | RNA / oligonucleotide | HBV RNA (X and S transcripts) | not yet graded | No reviewed efficacy summary in this indication | |
| Envafolimab | Phase 2 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Hepalatide | Phase 2 | Peptide | NTCP | not yet graded | No reviewed efficacy summary in this indication | |
| Libevitug (HH-003) | Phase 2 | Monoclonal antibody | HBV/HDV large envelope protein (PreS1 domain) | not yet graded | No reviewed efficacy summary in this indication | |
| Metacavir | Phase 2 | Small molecule | HBV reverse transcriptase (nucleoside analog) | not yet graded | No reviewed efficacy summary in this indication | |
| REP 2139-Mg | Phase 2 | — | HBsAg release (nucleic acid polymer) | not yet graded | No reviewed efficacy summary in this indication | |
| T101 | Phase 2 | Biologic (subtype unspecified) | HBV core, polymerase and envelope antigens | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3810 | Phase 2 | — | TLR8 | not yet graded | No reviewed efficacy summary in this indication | |
| CRMA-1001 | Phase 1/2 | Gene therapy / editing | HBV genome (cccDNA and integrated DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| Hepadvax | Phase 1/2 | Vaccine | HBsAg (PreS) immunization | not yet graded | No reviewed efficacy summary in this indication | |
| Human Serum Albumin / Interferon Alpha2b Fusion Protein | Phase 1/2 | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| LW231 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| PA1010 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3038 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| ACT201 | Phase 1 | RNA / oligonucleotide | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| CB06-036 | Phase 1 | — | TLR8 | not yet graded | No reviewed efficacy summary in this indication | |
| DA-2803 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Entecavir (Cavir) | Phase 1(overall) | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| HECN30227 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| SA1211 | Phase 1 | RNA / oligonucleotide | Hepatitis B virus RNA (dual-target siRNA) | not yet graded | No reviewed efficacy summary in this indication | |
| TVAX-028 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Adefovir Dipivoxil (Hepsera) | Discontinued | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Obeticholic Acid (Ocaliva) | Discontinued | — | FXR | not yet graded | No reviewed efficacy summary in this indication | |
| Pamrevlumab | Discontinued | Monoclonal antibody | CTGF | not yet graded | No reviewed efficacy summary in this indication | |
| Telbivudine (Tyzeka) | Discontinued | — | HBV polymerase (reverse transcriptase) | Partial signal | NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed |
Upcoming events
No upcoming readouts on record for this asset.